BGPT: Paper Review: The role of glutathione-dependent enzymes in drug resistance

Explore by Goal

Quick Explanation Copied

Core claim: The review argues that glutathione (GSH) and GSH-dependent enzymes contribute to drug/carcinogen resistance by shaping redox balance and detoxication capacity, with emphasis on GSTs, GPx, GRD, and GGT systems, while stressing that these factors cannot fully explain resistance patterns on their own.

Long Explanation

Paper Review (Synthesis + Skeptical Critique)

Paper: “The role of glutathione-dependent enzymes in drug resistance”

Venue: Pharmacology & Therapeutics (as given in your extracted metadata)

Year: 1991 (as given in your extracted metadata)

1) Visual map of the argument (what the review claims)

The nodes reflect the review’s structured emphasis on GST/GPx/GRD/GGT and its explicit statement that GSH-dependent enzymes do not fully account for resistance patterns.

2) Evidence hierarchy the review uses (and where causality is strongest vs weakest)

Evidence lines explicitly listed/used by the review:

Oxidative-stress responsiveness: enzymes maintaining GSH and several GSH-dependent enzymes elevate after oxidative stress.
Association with resistance phenotypes: resistant cell lines show increased GSH levels and increased GSH-dependent enzymes.
Tissue/preneoplasia association: resistant bone marrow/lung cells and resistant preneoplastic foci show elevated GSH.
Intervention directionality: GSH depletion sensitizes cells to diverse cytotoxic drugs including alkylating agents, cisplatin, and adriamycin.
Augmentation directionality: augmenting cellular GSH protects cells from those toxic effects (in vivo and in vitro).

Skeptical take on causality (what is strongest vs not):

Stronger causality: the review repeatedly points to intervention-style evidence (GSH depletion sensitizes; GSH augmentation protects) and to gene/enzyme perturbation via expression studies (e.g., GST cDNA expression can increase resistance in some systems).
Weaker causality / important caveats: the review explicitly notes issues such as tumor/normal heterogeneity, limited interpretability of tumor-versus-normal comparisons, multiplicity of resistance mechanisms (multidrug resistance), and the fact that resistance patterns are not fully explained by GST/GSH systems alone.

3) Mechanistic subsections (GST, GPx, GRD, GGT) — what the review emphasizes

GST (Glutathione S-transferases)

The review frames GSTs as catalyzing formation of GSH conjugates for electrophilic foreign/drug substrates, with conjugates either excreted or further metabolized; it also discusses additional roles such as peroxidase-like activity and drug/hormone binding as potentially relevant to resistance phenotypes.
It distinguishes intrinsic versus acquired resistance and argues GST elevations appear across multiple phylogenies and are seen in multiple intrinsic resistant human tumors, but it also says direct causal evidence for some markers (e.g., GST pi as a contributor to failure) can remain elusive.

GPx (Glutathione Peroxidase)

The review describes GPx as detoxifying hydrogen peroxide and lipid hydroperoxides, highlighting selenium-dependent GPx requiring selenocysteine incorporation and contrasting activity distinct from alpha-class GSTs.
It presents mixed/selective observations: some selected resistant lines show large GPx activity increases, while other resistant selections do not, implying multiple resistance mechanisms and cell-line dependence.

GRD (Glutathione Reductase)

The review describes GRD as maintaining the GSH:GSSG reducing ratio, and notes that while GRD is not crucial for survival in E. coli mutants, cancer-relevant contexts may relate to GSH-mediated drug resistance.

GGT (Gamma-Glutamyl Transpeptidase)

The review emphasizes GGT as cleaving intact GSH and transferring the gamma-glutamyl moiety, with membrane topology described and with elevated GGT reported in various tumors and resistant cell lines; it links elevated GGT to possible local increases in available intracellular GSH and reduced stress during promotion in carcinogenesis.

4) Strengths of the review (what it does well)

Clear mechanistic framing around the centrality of the GSH redox system and multiple GSH-dependent enzyme classes.
Explicit caveats about multifactorial resistance and about interpretational difficulties (heterogeneity, model-vs-tumor mismatch).
Attempts to distinguish causality from correlation by referencing intervention and expression strategies, while acknowledging when evidence is still incomplete.

5) Weaknesses / red flags (scientific skepticism points)

Review-style selection & over-weighting: as a narrative review, it may privilege studies that support GSH-enzyme involvement while underweighting contradictory or non-replicating findings; the paper itself acknowledges that single-enzyme explanations are unlikely, but the review’s persuasive framing could still suffer from typical narrative bias. (This is a general methodological risk for narrative reviews; the specific paper-level limitations described are multifactorial and model relevance issues.)
Heterogeneity & compartmentalization: even within the GSH system, the review notes uncertainty about how much bulk GSH/enzyme levels reflect the functional compartmentalization relevant to drug action.
Magnitude transferability: the review notes that fold-resistance from expression studies in some mammalian systems is often low relative to levels in drug-selected resistant lines, implying that resistance likely requires multiple co-occurring changes.
Model-to-human generalization: the review explicitly points out cell-culture kinetics (e.g., GSH decreases across passages in some culture systems) and argues xenografts may be more relevant.

6) What would disprove or substantially revise the review’s central thesis?

If perturbations of the GSH system fail to change drug sensitivity in properly controlled systems for the drugs emphasized (alkylating agents and radical-mediated drugs), that would weaken causal claims. The review already frames depletion/augmentation experiments as directional, so falsification would require failures of that directionality.
If resistance remains unchanged while GSH-dependent enzyme activity is neutralized (and while other known resistance mechanisms are controlled for), that would argue these enzymes are markers/epiphenomena rather than drivers. The review states resistance is multifactorial, so the falsifying scenario must show that removing the GSH systems does not shift resistance at all across contexts.

7) Quick navigation: deeper BGPT author-focused queries

Buttons link to bespoke BGPT author summaries.

Feedback:

Updated: April 11, 2026